Stugeron Tablet is the trade name of Cinnarizine, which is an anti-histaminic agent and a calcium channel blocker. It is the most commonly used drug in many countries for motion sickness and vertigo.
Stugeron Tablet is most commonly prescribed for vertigo, migraines and motion sickness.
The most common side effects that occur when patients take Stugeron Tablet for a short duration are as follows:
Long term use of Stugeron Tablet more than the duration recommended by a physician may result in the following symptoms. If a patient develops a severe anaphylactic reaction to Stugeron, consultation with an emergency care physician is mandatory. The adverse reactions may include
The above list is not all-inclusive and if the patient experiences any unexplained symptom, he should immediately seek the advice of a registered medical practitioner.
Stugeron Tablet (Cinnarizine) is an oral medication and is usually administered per oral twice or thrice daily for middle ear disorders causing problems with balance. In case of motion sickness, the drug is preferably taken one tablet 2 hours before travel orally and once every 4 hours during travel to avoid nausea and vomiting induced by travel.
Stugeron Tablet begins to act within about an hour after oral administration and its effect may last up to 6-8 hours.
The above mentioned is only the general recommended dosage. Every individual’s condition and metabolism is different. Dosage will depend on the age of the patient, the gender, the severity of the current medical condition, previous medical conditions and other factors. Hence, it is highly recommended that Stugeron (Cinnarizine) be taken according to the advice of a registered medical practitioner.
Stugeron Tablet contains 25 mg of the active ingredient Cinnarizine. Cinnarizine belongs to the diphenylmethylpiperazine group of drugs. It acts as both an antihistaminic and a calcium channel blocker. Additionally, it also exhibits antiserotonergic and antidopaminergic actions.
Mechanism of Action of Stugeron (Cinnarizine)
Cinnarizine is a selective antagonist of T-type voltage-gated calcium ion channels in the type II vestibular hair cells of the inner ear. Thus, it blocks the channels and keeps them inert resulting in stoppage of influx of calcium ions through the cell membrane. This results in reduced sensitivity fo vestibular receptors and hence relief from motion induced sickness symptoms and migraine symptoms.
Cinnarizine also acts as an antihistaminic by binding to H1 histamine receptors and blocking them. This way it prevents histamine from activating the receptors. Apart from these effects, Cinnarizine (Stugeron) also blocks serotonin and dopamine receptors exerting antiserotonergic and antidopaminergic actions.
During initial treatment, Stugeron Tablet may cause drowsiness and excessive sleepiness. People operating heavy machinery or driving long distances are advised to exercise caution as the medication may make the patient feel dizzy, sleepy, tired and decrease alertness. Stugeron is best avoided in pregnant and lactating mothers as studies are still pending on the safety of cinnarizine in both these conditions.
Cinnarizine accentuates the depressing effects of alcohol and when taken concomitantly may cause excessive drowsiness and loss of consciousness.
Similarly, Cinnarizine should be avoided when other central nervous system drugs such as tricyclic antidepressants or CNS depressants are being used by the patient.
In patients with hepatic or renal insufficiency, precautionary measures have to be taken as there are no reports regarding the safe use of cinnarizine in such conditions. Dose adjustment may be necessary or dose alteration with another drug may be required. Hence Stugeron Tablet should only be taken after consultation with a registered physician.
Parkinson’s disease patients should be prescribed Stugeron sparingly or only when benefits outweigh the risks. Patients with Porphyria should preferably avoid the drug due to an increase in adverse effects.
In patients taking drugs such as Amitriptyline, Tramadol, Chlorpromazine or Diazepam, close and frequent monitoring is essential when Stugeron Tablet is co-administered as there may be synergistic depressant effects on the Central Nervous system.
Disclaimer : Docprime doesn’t endorse or take any guarantee of the accuracy or completeness of information provided under this article and these are the views strictly of the writer. Docprime shall not be held responsible for any aspect of healthcare services administered with the information provided on this article.